Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Search Results

Refine Your Search

By Sector
Sort by: Date|Relevance

Announcement of Binding Agreement on Salar de Arizaro, Argentina & Company

Lithium Chile: Announcement of Binding Agreement on Salar de Arizaro, Argentina & Company On Monday, Lithium Chile announced a very exciting addition to its Lithium Portfolio. This new property gives the company location diversification and an expedited timetable to fe...
Featured Submission | May 28, 2021 |

Analyst Upgrade Ignites Duchenne's Muscular Dystrophy Research Firm's Shares

Solid Biosciences' shares are up by more than 40% today after Chardan Capital Markets upgraded the firm's shares from "neutral" to "buy" and raised its price target from $7.50 to $10.00/share. Duchenne muscular dystrophy (DMD) research firm Solid Biosciences ...
Streetwise Reports | August 20, 2019 |

Why Provention Bio Is in My Portfolio

Quite often when I write about companies I'm just about the only one doing so. It's in these situations that Tailwinds can add value by not only highlighting our investment thesis, but in educating investors about a company for which there is little to no publicly avail...
Streetwise Reports | August 26, 2019 |

Gold's Epochal Breakout Will Not Be Negated by a Correction

Technical analyst Clive Maund charts the reasons why the recent gold breakout is genuine. It has been a truly glorious month for gold, and the purpose of this update is to point out firstly that the gold breakout of the past week was genuine and secondly tha...
Streetwise Reports | July 3, 2019 |

Kiniksa Pharma Awarded FDA Breakthrough Therapy Status for Pericarditis Treatment Drug

Shares of Kiniksa Pharmaceuticals opened nearly 30% higher today after the firm reported that the FDA granted Breakthrough Therapy designation for Rilonacept for the treatment of recurrent pericarditis. This morning, Hamilton, Bermuda based biopharmaceutical company ...
Streetwise Reports | November 21, 2019 |

Savara Shares Double After FDA Grants Breakthrough Therapy Status for aPAP Treatment

Shares of Savara opened nearly 140% higher today after the orphan lung disease company advised that the FDA has granted Breakthrough Therapy designation for the firm's Molgradex for treatment of Autoimmune Pulmonary Alveolar Proteinosis (aPAP). This morning orphan lun...
Streetwise Reports | January 2, 2020 |

Genprex Shares Soar 250% on FDA Fast Track Designation for Lung Cancer Drug

Genprex's shares spiked 380% higher in morning trading as the company reported that the FDA granted Fast Track Designation for its Oncoprex immunogene therapy in combination with EGFR inhibitor osimertinib. This morning, Genprex Inc. (GNPX:NASDAQ) , which "utilizes a...
Streetwise Reports | January 22, 2020 |

U.S.-Based Biotech 'Growing into a Giant with AI'

How Moderna uses and benefits from digitization and artificial intelligence are described in a ROTH Capital Partners report. In a March 5 research note, ROTH Capital Partners analyst Yasmeen Rahimi reported that a site visit to Moderna Inc.'s (MRNA:NASDAQ) ...
Streetwise Reports | March 9, 2020 |

Edesa Shares Double Upon Gaining Approval to Initiate Phase 2/3 COVID-19 Study

Shares of Edesa Biotech traded more than 100% higher after the company reported that it had received regulatory approval from Health Canada to initiate a Phase 2/3 study of its investigational drug EB05 in COVID-19. Clinical-stage biopharmaceutical company Edesa B...
Streetwise Reports | June 16, 2020 |

'Undervalued' Biopharma Gets Breakthrough Status for Alzheimer's Agitation Drug

Axsome Therapeutics' latest news and clinical outlook are discussed in an H.C. Wainwright & Co. report. In a June 30 research note, H.C. Wainwright & Co. analyst Ram Selvaraju reported that the U.S. Food and Drug Administration (FDA) designated Axsome Therapeutics...
Streetwise Reports | July 2, 2020 |
1 2